Global Wealth Management Investment Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Global Wealth Management Investment Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-9	Closed	-$2K	–	726
2019 Q3	$2K	Hold	9	–	–	﹤0.01%	546
2019 Q2	$2K	Hold	9	–	–	﹤0.01%	600
2019 Q1	$2K	Hold	9	–	–	﹤0.01%	580
2018 Q4	$1K	Buy	+9	New	+$1.56K	﹤0.01%	678

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Global Wealth Management Investment Advisory's VRTX Position: Q4 2019 in Review

Global Wealth Management Investment Advisory sold out of Vertex Pharmaceuticals (VRTX) in Q4 2019, closing a stake of 9 shares — an estimated $2K sold.

Global Wealth Management Investment Advisory first reported a position in VRTX in Q4 2018 and held it in 4 quarters. The position peaked at $2K in Q3 2019. 814 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

Global Wealth Management Investment Advisory reported no remaining Vertex Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Global Wealth Management Investment Advisory sold 9 Vertex Pharmaceuticals shares in Q4 2019, an estimated $2K.
Global Wealth Management Investment Advisory first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 4 quarters.
Global Wealth Management Investment Advisory's Vertex Pharmaceuticals position peaked at $2K in Q3 2019.
814 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on Global Wealth Management Investment Advisory's 13F filing for Q4 2019, filed 14 Feb 2020.